• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Xusbir is almost here. It will crush all HCV opponents

















Yes, you will crush them. Until the next best thing comes along. And it will. And it won't be from Gilead.

Now its Xusbir +Peg/riba; in a year its Xusbir co-formulated w/ledipasvir (5885) I don't know the name yet. In about a year out from that will be Xusbir + GS-5816 (a pan-genotypic NS5a) Any more questions?
 








Glad its Friday. So the rumor is that Xusbir will be priced at $84,700. I think that is pretty much what everyone was thinking. No real surprise.

I just hope that doesn't box us in If we have to be "flexible" 1 year from now. It will not matter. Even if Abbvie comes out a month or two ahead of us - we will still dominate. Xusbir and its co-formulated follow on will own this market!!!